VINEET LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.05 INR | -2.13% |
|
+3.19% | -32.58% |
| May. 30 | Vineet Laboratories CEO Resigns | MT |
| May. 29 | Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Executive Director | CI |
| Sales 2022 | 1.91K 159K | Sales 2023 | 2.12K 177K | Capitalization | 382M 31.84B |
|---|---|---|---|---|---|
| Net income 2022 | 66M 5.51B | Net income 2023 | 12M 1B | EV / Sales 2022 | 273,707 x |
| Net Debt 2022 | 83.97M 7B | Net Debt 2023 | 305M 25.41B | EV / Sales 2023 | 323,255 x |
| P/E ratio 2022 |
6.62
x | P/E ratio 2023 |
30.5
x | Employees | 72 |
| Yield 2022 |
2.1% | Yield 2023 |
-
| Free-Float | 49.77% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.13% | ||
| 1 week | +3.19% | ||
| 1 month | -3.08% | ||
| 3 months | +2.42% | ||
| 6 months | -18.87% | ||
| Current year | -32.58% |
1 week
54.90
64.50
1 month
50.0564.50
Current year
46.6083.60
1 year
46.6088.90
3 years
38.35124.00
5 years
38.35124.00
10 years
38.35124.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 74 | 16-11-09 | |
| Compliance Officer | - | Nov. 09 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 16-11-09 | |
| Director of Finance/CFO | 74 | 16-11-09 | |
| Director/Board Member | 50 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 55.05 | -2.13% | 26,497 |
| 24-05-30 | 56.25 | -4.17% | 59,826 |
| 24-05-29 | 58.7 | +4.82% | 311,704 |
| 24-05-28 | 56 | -8.79% | 117,229 |
| 24-05-27 | 61.4 | +15.09% | 497,943 |
Delayed Quote NSE India S.E., May 31, 2024 at 07:43 am EDT
More quotes
Vineet Laboratories Limited is engaged in the business of drug intermediates and bulk drugs. The Company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. It also exports API intermediates, fine chemicals, and custom synthesis molecules.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -32.58% | 6.22M | |
| +40.73% | 734B | |
| +32.83% | 591B | |
| -6.30% | 350B | |
| +15.15% | 315B | |
| +4.05% | 276B | |
| +15.00% | 238B | |
| +9.78% | 206B | |
| -5.52% | 204B | |
| +6.17% | 161B |
- Stock Market
- Equities
- VINEETLAB Stock
